5+ years of experience
Concerned about your lack of experience? Learn More...
Employment Type:
Full time
Job Category:
Vendor Contract Lead, Clinical Procurement
Biogen | Cambridge, Massachusetts
Tell Us More About Your Job Preferences
By telling us what you think of this job, we can help find jobs that match your interests. If you want to see more jobs like this, click on the smiley face. Or if this job isn't what you are looking for, click the frowny face. Learn More...

Follow This Company

Job Description

External Posting TitleVendor Contract Lead, Clinical Procurement
Job DescriptionThe Vendor Contract Lead (VCL) role provides strategic vendor category leadership within the Clinical Services Procurement (CSP) team. The VCL collaborates with the Strategic Sourcing Category Lead during the vendor selection process to ensure Master Agreement terms can be operationalized within CSP. The VCL ensures a best in class approach with regard to vendor outsourcing and contracting for their vendor categories. This includes leading the development, implementation & execution of a vendor outsourcing strategy within their category. Responsible for representing CSP in governance forums, as needed.

1. Contract Delivery and Governance
a) Has overall accountability for the completion of all clinical vendor SOWs and purchase requisitions in accordance with company financial/legal controls and MSA terms (if applicable), ensuring alignment with study timelines to meet business demand
b) Independently leads and completes key High Value/Low Volume SOWs and purchase requisitions etc. and streamline processes to eliminate non-value added work
c) May utilize VCMs to manage volume of work as necessary
d) Channels business to preferred vendors / MSAs; manages exceptions

2. Lead the implementation & execution of vendor outsourcing strategy within category:
a. Create & implement category contracting governance, processes, tools & templates to limit/eliminate contract exceptions & change orders
b. Provides forecasts to vendors and verifies they have capacity to meet demand; manages exceptions
c. Develops market expertise in the assigned category
d. Representation in Governance Forum for Vendor Category (if needed)

3. Sourcing Support: Above and Below the Purchasing Policy Threshold:
a. With input from strategic sourcing and business stakeholders, lead/oversee sourcing & negotiate Master Service Agreements & Service Level Agreements for services below the purchasing policy threshold & not covered by a sourcing strategy/preferred vendor
b. Participates in strategic sourcing projects as clinical services procurement SME

4. Lead/participate in the creation and maintenance of department processes, tools and templates

5. Lead/participate in department and/or GCO/R&D initiatives that have direct impact to role

LocationCambridge, MA, US
Job CategoryClinical Operations, Finance
Requisition Number29541BR
QualificationsMinimum of 8+ years' experience in clinical vendor management/clinical outsourcing within the pharmaceutical/biotechnology industry

Extensive experience in vendor contract negotiation and execution across SRC and Phase I-IV trials.

Strong knowledge and experience of clinical vendor strategy, contracting and financial processes; experience with procure to pay systems (e.g. Oracle, MarkView, etc.)

Knowledge of the clinical development process (Pharma R&D and Clinical) with a clear understanding of operational and quality (GCP) aspects

Strong financial negotiation skills

Excellent people and customer service skills demonstrating an ability to work as a team player within matrix teams, interacting with all levels of staff, both within and external to the company to establish good partnerships/alliances
EducationBachelor's Degree required

MBA or other related business experience is a plus (business acumen - translating operations into business benefit)
About BiogenCorporate Overview
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis (MS), has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS). Biogen also manufactures and commercializes biosimilars of advanced biologics. Our global organization of nearly 7,000 employees is committed to a single mission: making a meaningful difference in the lives of patients with few or no treatment options.
  • Biogen was founded in 1978 and today serves patients in nearly 70 countries.
  • A Fortune 500 company, Biogen in 2016 had revenues of $11.4 billion
  • Global headquarters in Cambridge, MA, and international headquarters in Zug, Switzerland
Our Science
We aspire to have the greatest impact on patients and science of any biotechnology company in the history of our industry. To us, that means creating novel medicines that benefit individuals and society, and bringing new scientific understanding to diseases for which there are no adequate treatments.
  • For nearly two decades Biogen has led in the research and development of new therapies to treat MS, including the most prescribed oral treatment in the world. Now our research is driving revolutionary new MS treatments with the goal of reversing or even repairing damage caused by the disease.
  • We are now applying our neurological expertise to solve some of most challenging and complex diseases of the brain, including Alzheimer's disease, Parkinson's disease, and ALS.
  • As we uncover new insights into human biology, Biogen is employing cutting-edge technologies to discover potential treatments for rare and genetic disorders.
  • Biogen is revolutionizing biologics manufacturing, developing the industry's most advanced plants and processes. This expertise is used to produce both original innovative therapies and biosimilars that expand patient access to lower-cost medicines.
Our Corporate Citizenship
The same intellectual discipline and passion that drives our science is reflected in our corporate citizenship, environmental sustainability, and commitment to diversity and inclusion. As a company, we are focused on improving science education and limiting the impact of our company on the environment. In 2015, we became a carbon neutral company and ranked first place on Newsweek's 2015 Green Rankings, and we are an industry leader on the Dow Jones Sustainability World Index. Biogen was named to Science's list of Top Employers of 2015 and in 2017 received a perfect score of 100 for the fourth consecutive year on the Human Rights Campaign (HRC) Corporate Equality Index, which also named Biogen as one of its Best Places to Work.

All qualified applicants will receive consideration for employment without regard to sex, gender identity or expression, sexual orientation, marital status, race, color, national origin, ancestry, ethnicity, religion, age, veteran status, disability, genetic information or any other basis protected by federal, state or local law. Biogen is an E-Verify Employer in the United States.

Please be advised that all legitimate correspondence from a Biogen employee will come from "@biogen.com" email accounts.

About Biogen

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company's products address diseases such as multiple sclerosis, lymphoma and rheumatoid arthritis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is used in the treatment of relapsed or refractory low-grade or follicular, CD20-positive, and B-cell, non-Hodgkin's lymphomas (B-cell NHLs). TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. It also has product candidates, such as BG-12 (acquired with the purchase of Fumapharm), ANTI-CD80 antibody/(galiximab), ANTI-CD23 antibody/(lumiliximab), Ocrelizumab/(Humanized ANTI-CD20 Antibody) and Lixivaptan.In January 2007, the Company completed the acquisition of Syntonix Pharmaceuticals, Inc. (Source: 10-K)

This company profile was created by AfterCollege and is about Biogen. This page is not endorsed by or affiliated with Biogen. For questions regarding company profiles, please email: care@aftercollege.com.